**Improved overall survival and decreased metastasis with adjuvant 5-fluorouracil and platinum chemotherapy after definitive concurrent chemoradiotherapy for N3 nasopharyngeal cancer: A registry-based analysis**

Mu-Hung Tsai1,2, Shang-Yin Wu3, Tsung Yu4, Sen-Tien Tsai5, Yuan-Hua Wu1\*

1 *Department of Radiation Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan*

2 *Institute of Computer Science and Information Engineering, National Cheng Kung University, Tainan, Taiwan*

3 *Division of Hematology/Oncology, Department of Internal Medicine, National*

*Cheng Kung University Hospital, College of Medicine, National Cheng Kung*

*University, Tainan, Taiwan*

4 *Department of Public Health, College of Medicine, National Cheng Kung University, Tainan, Taiwan*

5 *Department of Otolaryngology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan*

**Supplementary Figure 1** Selection of study cohort. Abbreviations: IMRT, intensity-modulated radiotherapy; VMAT, volumetric modulated arc therapy; CCRT, concurrent chemoradiotherapy; TCR, Taiwan Cancer Registry; NHI, National Health Insurance; PF, platinum-fluorouracil regimen.

****

**Supplementary Figure 2** Forest plot of subgroup analysis on effect of adjuvant PF chemotherapy shows a consistent improvement in survival in all subgroups. *P*-values are shown for tests of interaction between the effect of adjuvant PF chemotherapy and given covariates. No significant interaction between subgroups and adjuvant chemotherapy was found.



**Supplementary Figure 3** Landmark analyses restricted to patients surviving over (a) 12 months; (b) 18 months; (c) 24 months all show an improved survival in the adjuvant PF chemotherapy group, compatible with results of the primary analysis.



**Supplementary Table 1** Univariable and multivariable Cox proportional hazards model for distant metastasis-free survival (n = 310).

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Univariable** |  |  | **Multivariable** |  |
| **Variable** | **Hazard ratio (95% CI)** | ***p*-value** |  | **Hazard ratio (95% CI)** | ***p*-value** |
| **Age, continuous** | 0.98 (0.95-1.02) | 0.32 |  | 0.97 (0.93-1.00) | 0.08 |
| **Sex** |  |  |  |  |  |
| Male | Reference |  |  | Reference |  |
| Female | 2.45 (1.06-5.67) | 0.04 |  | 2.16 (0.91-5.12) | 0.08 |
| **Histology** |  |  |  |  |  |
| Carcinoma, NOS | 0.57 (0.17-1.92) | 0.36 |  | 0.58 (0.16-2.07) | 0.40 |
| Squamous cell carcinoma, keratinizing or NOS | 0.00 (0.00-Inf) | 1.00 |  | 0.00 (0.00-Inf) | 1.00 |
| Squamous cell carcinoma, non-keratinizing | Reference |  |  | Reference |  |
| **Clinical T classification** |  |  |  |  |  |
| T1 | Reference |  |  | Reference |  |
| T2 | 2.04 (0.76-5.48) | 0.16 |  | 1.92 (0.71-5.24) | 0.20 |
| T3 | 1.30 (0.46-3.67) | 0.62 |  | 1.48 (0.52-4.23) | 0.46 |
| T4 | 0.23 (0.03-1.81) | 0.16 |  | 0.19 (0.02-1.55) | 0.12 |
| **Clinical N classification** |  |  |  |  |  |
| N3a | Reference |  |  | Reference |  |
| N3b | 0.93 (0.39-2.19) | 0.86 |  | 0.94 (0.38-2.30) | 0.89 |
| **Adjuvant treatment** |  |  |  |  |  |
| Observation | Reference |  |  | Reference |  |
| Adjuvant PF chemotherapy | 0.13 (0.03-0.54) | 0.005 |  | 0.11 (0.02-0.46) | 0.003 |

Abbreviations: CI, confidence interval; NOS, not otherwise specified; Inf, infinity